Physician

Charles Frederick Degenhardt, M.D.

According to 2025 Medicare claims, Charles Degenhardt, M.D. (NPI: 1467651711) practices rheumatology in the Savannah, GA market, with the plurality of this provider's patient population coming from Chatham, GA. This provider's primary affiliated billing organization is SOUTHEASTERN RHEUMATOLOGY ALLIANCE (NPI: 1114795663; TIN: 933460719) and primary practice location at 31404-6234. Degenhardt is affiliated with the Southeastern Health Partners (ACO ID: A3325), participating under the MSSP model.

Degenhardt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 793 traditional Medicare patients, billed 202,632 HCPCS/CPT codes, and received $2,518,921 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,774 prescription claims across 446 beneficiaries totaling $1,931,985 in drug costs, led by Enbrel Sureclick (Etanercept). 2017 DME data shows 12 claims. Open Payments data shows 101 records totaling $2,412. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $145,102 to $2,518,921. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $322,332 to $1,931,985. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	179	16,306	$145,102
2016	277	30,957	$409,119
2017	301	41,668	$661,877
2018	320	97,834	$1,454,515
2019	365	120,809	$2,126,279
2020	460	147,157	$2,743,959
2021	477	148,332	$2,765,594
2022	425	169,332	$2,526,162
2023	435	185,898	$2,865,892
2024	793	202,632	$2,518,921

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	254	1,028	$322,332
2016	269	1,677	$688,790
2017	308	2,118	$947,530
2018	327	2,308	$976,394
2019	369	2,146	$967,418
2020	417	2,390	$1,549,694
2021	402	2,098	$1,934,745
2022	377	1,819	$2,162,916
2023	345	1,640	$2,081,436
2024	446	1,774	$1,931,985

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	12	$209
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	298	871	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	495	828	$91
80053	Blood test, comprehensive group of blood chemicals	189	243	$10
86140	Measurement c-reactive protein for detection of infection or inflammation	192	240	$5
85652	Red blood cell sedimentation rate, to detect inflammation, automated	193	241	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	84	2,632	$689,380
Simponi	Golimumab	32	1,274	$259,327
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	12	336	$212,680
Humira(Cf) Pen	Adalimumab	21	616	$147,562
Xeljanz Xr	Tofacitinib Citrate	13	390	$71,250

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	101	$2,412	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Frederick Degenhardt, M.D.?

Tedicare shows public-source Medicare data for Charles Frederick Degenhardt, M.D. (NPI 1467651711), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Frederick Degenhardt, M.D. have ACO affiliation data?

Charles Frederick Degenhardt, M.D. is shown with ACO affiliation data for Southeastern Health Partners (MSSP, ACO ID A3325).

What billing organization is linked to Charles Frederick Degenhardt, M.D.?

Charles Frederick Degenhardt, M.D. is linked to SOUTHEASTERN RHEUMATOLOGY ALLIANCE (billing NPI 1114795663) in the available physician profile data.

Does Charles Frederick Degenhardt, M.D. have Open Payments data?

Charles Frederick Degenhardt, M.D. has 101 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.